Bulk Manufacturer of Controlled Substances Application: Navinta LLC, 4955 [2022-01815]
Download as PDF
<![CDATA[
Federal Register / Vol. 87, No. 20 / Monday, January 31, 2022 / Notices
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. CRT 142]
[Docket No. DEA–933]
Bulk Manufacturer of Controlled
Substances Application: Navinta LLC
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Navinta LLC, has applied to
be registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
SUMMARY:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before April 1, 2022. Such persons
may also file a written request for a
hearing on the application on or before
April 1, 2022.
DATES:
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
ADDRESSES:
In
accordance with 21 CFR 1301.33(a), this
is notice that on October 18, 2021,
Navinta LLC, 1499 Lower Ferry Road,
Ewing, New Jersey 08618–1414, applied
to be registered as a bulk manufacturer
of the following basic class(es) of
controlled substance(s):
SUPPLEMENTARY INFORMATION:
Drug
code
khammond on DSKJM1Z7X2PROD with NOTICES
4-Anilino-N-phenethyl-4-piperidine (ANPP).
Levomethorphan .....................
Levorphanol ............................
Noroxymorphone ....................
Fentanyl ..................................
Schedule
8333
II
9210
9220
9739
9801
II
II
II
II
The company plans to bulk
manufacture active pharmaceutical
ingredients (API) quantities of the listed
controlled subsances for validation
purpose and the Food and Drug
Adminstration approval. No other
activities for these drug codes are
authorized for this registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022–01815 Filed 1–28–22; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:38 Jan 28, 2022
Civil Rights Division,
Department of Justice.
ACTION: Notice.
AGENCY:
This notice announces the
availability on the Department of
Justice’s website of an updated report
regarding the legal and evidentiary
frameworks that justify the continued
use of race or sex, in appropriate
circumstances, by federal agencies to
remedy the current and lingering effects
of past discrimination in federal
contracting programs.
FOR FURTHER INFORMATION CONTACT:
Andrew Braniff, Deputy Section Chief,
Employment Litigation Section, Civil
Rights Division, Department of Justice,
(202) 514–3831, EMP.Lit@crt.usdoj.gov.
If you use a telecommunications device
for the deaf (TDD) or a text telephone
(TTY), call the Federal Relay Service
(FRS), toll free, at 1–800–877–8339.
SUPPLEMENTARY INFORMATION: A
substantial body of evidence, both
quantitative and qualitative,
demonstrates the continued
pervasiveness of discriminatory barriers
that impede the full and fair
participation of businesses owned by
women and people of color in
government contracting. The nature and
breadth of the evidence discussed in the
report updates and expands on prior
reports—in 1996 and 2010—and
supports the compelling interest in the
continued use of federal programs that
contain remedial measures to eliminate
discriminatory barriers to contracting
opportunities for businesses owned by
women and people of color. See
Adarand v. Constructors, Inc. v. Pena,
515 U.S. 200 (1995).
Section I of the report provides an
overview of the legal landscape
surrounding constitutional challenges to
the use of race and sex in contracting
programs that are subject to strict and
intermediate scrutiny, including a
discussion of some recent cases
challenging various federal and state
contracting programs. Section II reviews
a substantial body of statistical evidence
published in the last decade, which
demonstrates the existence of significant
disparities in the amount of public
contracting dollars going to businesses
owned by women and people of color as
compared to their availability for such
contracts. Section III explores the
various ways that discriminatory
SUMMARY:
Notice of application.
Controlled
substance
Notice of Report on Lawful Uses of
Race or Sex in Federal Contracting
Programs
Jkt 256001
PO 00000
Frm 00124
Fmt 4703
Sfmt 4703
4955
barriers can limit access to contracting
markets, resulting in the statistical
disparities identified in Section II.
These include race and sex
discrimination by procurement agencies
and prime contractors, whether overt or
subtle; exclusion from business
networks crucial to making the
connections necessary to learn about
and compete effectively for contracting
opportunities; and discrimination by
bonding companies and suppliers.
Section IV discusses stark disparities in
the formation and success of businesses
owned by women and people of color as
compared to other businesses. Section V
addresses discriminatory barriers that
impose significant burdens on
businesses owned by women and
people of color—affecting both their
ability to access capital to form and
grow businesses in the first instance as
well as their ability to compete
effectively for contracts. Finally, Section
VI addresses how the economic
downturn that began in 2020 as a result
of the COVID–19 pandemic has
disproportionately affected businesses
owned by women and people of color.
Evidence discussed in the report is
listed in the three appendices.
Appendix A identifies congressional
hearings from 2010 to 2021 that address
challenges facing business owned by
women and people of color. Appendix
B identifies dozens of disparity studies
published between 2010 and 2021.
Appendix C identifies additional
studies and documentation pertaining to
the issues discussed in the report.
The report is available on the
Department of Justice’s website at:
https://www.justice.gov/crt/page/file/
1463921/download.
Dated: January 20, 2022.
Johnathan Smith,
Deputy Assistant Attorney General, Civil
Rights Division.
[FR Doc. 2022–01478 Filed 1–28–22; 8:45 am]
BILLING CODE 4410–13–P
DEPARTMENT OF LABOR
Occupational Safety and Health
Administration
[Docket No. OSHA–2021–0010]
Federal Advisory Council on
Occupational Safety and Health
Occupational Safety and Health
Administration (OSHA), Labor.
ACTION: Extension of Comment Period.
AGENCY:
The Secretary of Labor
(Secretary) invites interested parties to
submit nominations for individuals to
SUMMARY:
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 87, Number 20 (Monday, January 31, 2022)]
[Notices]
[Page 4955]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-01815]
[[Page 4955]]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-933]
Bulk Manufacturer of Controlled Substances Application: Navinta
LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Navinta LLC, has applied to be registered as a bulk
manufacturer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before April 1, 2022.
Such persons may also file a written request for a hearing on the
application on or before April 1, 2022.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on October 18, 2021, Navinta LLC, 1499 Lower Ferry Road,
Ewing, New Jersey 08618-1414, applied to be registered as a bulk
manufacturer of the following basic class(es) of controlled
substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
4-Anilino-N-phenethyl-4-piperidine 8333 II
(ANPP).
Levomethorphan.......................... 9210 II
Levorphanol............................. 9220 II
Noroxymorphone.......................... 9739 II
Fentanyl................................ 9801 II
------------------------------------------------------------------------
The company plans to bulk manufacture active pharmaceutical
ingredients (API) quantities of the listed controlled subsances for
validation purpose and the Food and Drug Adminstration approval. No
other activities for these drug codes are authorized for this
registration.
Brian S. Besser,
Acting Assistant Administrator.
[FR Doc. 2022-01815 Filed 1-28-22; 8:45 am]
BILLING CODE P
